




Figure 1. Notification rate of suspected measles and rubella cases per 100,000 population by country. Central America, 2016-2020*

| Country | 2016 | 2017 | 2018 | 2019 | 2020 |
|--------------------|------|------|------|------|------|
| Costa Rica | 0.7 | 2.1 | 1.3 | 2.0 | 1.7 |
| Cuba | 13.1 | 12.5 | 22.6 | 28.9 | 13.5 |
| Dominican Republic | 1.6 | 3.2 | 1.7 | 1.6 | 0.4 |
| El Salvador | 0.0 | 4.3 | 8.1 | 8.6 | 2.7 |
| Guatemala | 1.2 | 1.1 | 3.0 | 2.1 | 0.3 |
| Haiti | 0.5 | 1.5 | 1.9 | 1.8 | 1.1 |
| Honduras | 0.6 | 1.7 | 2.2 | 4.0 | 1.2 |
| Mexico | 3.1 | 2.7 | 3.1 | 4.0 | 2.1 |
| Nicaragua | 2.0 | 3.7 | 4.6 | 10.5 | 1.8 |
| Panama | 1.4 | 1.2 | 1.7 | 1.6 | 0.7 |

■ ≥2.00 x 100,000 population
 ■ 1.00-1.99 x 100,000 population
 ■ <0.99 x 100,000 population

Figure 2. Notification of measles, rubella (MR) and COVID-19 cases by epidemiological weeks. Central America, 2020*



*Data as of epidemiological week 48, 2020. Source: Surveillance country reports sent to PAHO.

Only three countries in Central America achieved a homogeneous compliance with their notification rates for suspected measles and rubella (MR) cases in the years prior to the COVID-19 pandemic, while in the remaining seven countries the compliance was heterogeneous (Figure 1). However, the impact of the COVID-19 pandemic is notorious (figure 2), as a 45% reduction in MR suspected cases is observed from epidemiological week 15 of 2020 and further, which is also reflected in few countries having achieved the notification rate in the present year.

Table 1
Classification of Suspect Measles, Rubella, and Congenital Rubella Syndrome (CRS) Cases for Weeks 01-48, 2020

| Subregion and Country | Susp. Cases 2020 | Measles Confirmed 2020 | | | | Year/Week Last Conf. Measles case | Rubella Confirmed 2020 | | | Year/Week Last Conf. Rubella Case | Diagnosis of Discarded Cases 2020 | | Congenital Rubella Syndrome | | | Year/Week Last Conf. CRS Case | |
|-----------------------|------------------|------------------------|-------------|-----------|-------------|-----------------------------------|------------------------|----------|----------|-----------------------------------|-----------------------------------|--------------|-----------------------------|----------|----------|-------------------------------|---------|
| | | Clin. | Lab. | EPI link | Total | | Clin. | Lab. | Total | | Dengue | Others | Susp. | Conf. | CRS* | | |
| AND | BOL | 74 | 0 | 2 | ... | 2 | 2020-16 | 0 | 0 | 0 | 2006-03 | 17 | 53 | 0 | 0 | 0 | ... |
| | COL | 653 | 0 | 1 | ... | 1 | 2020-09 | 0 | 0 | 0 | 2012-31 | 0 | 494 | 331 | 0 | 0 | 2005-34 |
| | ECU | 136 | 0 | 0 | ... | 0 | 2020-06 | ... | ... | ... | 2004-49 | 1 | 110 | 0 | 0 | 0 | 2011-14 |
| | PER | 71 | 0 | 0 | ... | 0 | 2019-18 | 0 | 0 | 0 | 2009-04 | 0 | 65 | 0 | 0 | 0 | 2007-16 |
| | VEN | 562 | 0 | 0 | ... | 0 | 2019-33 | 0 | 0 | 0 | 2007-51 | 32 | 373 | 0 | 0 | 0 | ... |
| BRA | BRA | 17036 | 2830 | 5524 | ... | 8354 | 2020-43 | 0 | 0 | 0 | 2014-40 | 0 | 8188 | 33 | 0 | 0 | 2009-34 |
| CAP | CRI | 81 | 0 | 0 | ... | 0 | 2019-13 | 0 | 0 | 0 | 2001-39 | 5 | 48 | 81 | 0 | 0 | ... |
| | GTM | 55 | 0 | 0 | ... | 0 | 2018-03 | 0 | 0 | 0 | 2006-31 | 1 | 49 | 1 | 0 | 0 | 2005-00 |
| | HND | 105 | 0 | 0 | ... | 0 | 1998-16 | 0 | 0 | 0 | 2004-11 | 0 | 104 | 7 | 0 | 0 | 2001-00 |
| | NIC | 110 | 0 | 0 | ... | 0 | 1994-14 | 0 | 0 | 0 | 2004-19 | 10 | 93 | 22 | 0 | 0 | 2005-00 |
| | PAN | 28 | 0 | 0 | ... | 0 | 2011-20 | 0 | 0 | 0 | 2002-48 | 0 | 27 | 0 | 0 | 0 | ... |
| | SLV | 159 | 0 | 0 | ... | 0 | 2001-19 | 0 | 0 | 0 | 2006-30 | 0 | 159 | 181 | 0 | 0 | 2001-00 |
| CAR | CAR | 54 | 0 | 0 | ... | 0 | 2019-48 | 0 | 0 | 0 | 2008-18 | 0 | 50 | 12 | 0 | 0 | 1999-00 |
| LAC | CUB | 1408 | 0 | 0 | ... | 0 | 2019-24 | 0 | 0 | 0 | 2004-06 | 0 | 1408 | 0 | 0 | 0 | 1989-10 |
| | DOM | 40 | 0 | 0 | ... | 0 | 2011-18 | 0 | 0 | 0 | 2007-45 | 4 | 14 | 0 | 0 | 0 | ... |
| | HTI | 118 | 0 | 0 | ... | 0 | 2001-39 | 0 | 0 | 0 | 2006-21 | 0 | 97 | 43 | 0 | 0 | ... |
| MEX | MEX | 2440 | ... | 184 | 10 | 194 | 2020-23 | 0 | 0 | 0 | 2018-14 | 0 | 2093 | 0 | 0 | 0 | ... |
| NOA | CAN | ... | ... | 1 | ... | 1 | 2020-06 | 0 | 0 | 0 | 2019-50 | ... | ... | ... | ... | ... | 2018-39 |
| | USA | ... | ... | 13 | ... | 13 | 2020-48 | ... | ... | ... | 2019-03 | ... | ... | ... | ... | ... | 2017-00 |
| SOC | ARG | 326 | 0 | 60 | 1 | 61 | 2020-12 | 0 | 0 | 0 | 2019-47 | 3 | 261 | 0 | 0 | 0 | 2009-27 |
| | CHL | 43 | 0 | 2 | ... | 2 | 2020-03 | 0 | 0 | 0 | 2019-14 | 0 | 37 | 0 | 0 | 0 | ... |
| | PRY | 545 | 0 | 0 | ... | 0 | 1998-44 | 0 | 0 | 0 | 2005-21 | 2 | 489 | 6 | 0 | 0 | 2003-06 |
| | URY | 9 | 0 | 0 | 2 | 2 | 2020-07 | 0 | 0 | 0 | 2001-37 | 0 | 6 | 0 | 0 | 0 | ... |
| TOTAL | 24053 | 2830 | 5787 | 13 | 8630 | -- | 0 | 0 | 0 | -- | 75 | 14218 | 717 | 0 | 0 | -- | |

*Congenital Rubella Infection.

...No updated report received



Measles, Rubella, and Congenital Rubella Syndrome Surveillance in the Americas

Vol. 26, No. 48

Table No.2
Infection Source of Measles and Rubella Confirmed Cases
for the Period of Weeks 01-48, 2020

| Subregion and Country | | Measles | | | | Rubella | | |
|-----------------------|------|-----------|----------|-------------|-----------|----------|----------|----------|
| | | I | IR | En. | U | I | IR | U |
| AND | BOL | | | | 2 | | | |
| | COL | 1 | | | | | | |
| | ECU | | | | | | | |
| | PER | | | | | | | |
| | VEN | | | | | | | |
| BRA CAP | BRA | | | 8354 | | | | |
| | CRI | | | | | | | |
| | GTM | | | | | | | |
| | HND | | | | | | | |
| | NIC | | | | | | | |
| | PAN | | | | | | | |
| | SLV | | | | | | | |
| | CAR | | | | | | | |
| | LAC | | | | | | | |
| | CUB | | | | | | | |
| MEX | DOM | | | | | | | |
| | HTI | | | | | | | |
| NOA | MEX* | | | | | | | |
| | CAN | 1 | | | | | | |
| | USA | 12 | | | | | | |
| SOC | ARG | 7 | | | 54 | | | |
| | CHL | 2 | | | | | | |
| | PRY | | | | | | | |
| | URY | | 2 | | | | | |
| TOTAL | | 23 | 2 | 8354 | 56 | 0 | 0 | 0 |

I: Imported; IR: Import-related; En: Endemic case; U: Unknown.
*Pending final classification

Table No.3
Measles/Rubella Suspect Cases Under Investigation
for the Period of Weeks 01-48, 2020

| Country | Pending Cases 2019 | Cumulative 2020 | Week of Onset | | | | | | | % Pend. Cases |
|--------------|--------------------|-----------------|---------------|-----------|-----------|-----------|-----------|----------|----------|---------------|
| | | | 1-43 | 44 | 45 | 46 | 47 | 48 | | |
| BOL | 1 | 2 | 0 | 0 | 1 | 1 | 0 | ... | 3 | |
| COL | 0 | 158 | 158 | 0 | 0 | 0 | 0 | ... | 24 | |
| ECU | 7 | 25 | 25 | 0 | 0 | ... | ... | ... | 18 | |
| PER | 13 | 6 | 1 | 2 | 2 | 0 | 0 | 1 | 8 | |
| VEN | 19 | 155 | 152 | 0 | 0 | 3 | ... | ... | 28 | |
| BRA | 2597 | 495 | 454 | 22 | 8 | 11 | 0 | 0 | 3 | |
| CRI | 0 | 28 | 28 | 0 | 0 | 0 | 0 | 0 | 35 | |
| GTM | 0 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 9 | |
| HND | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | |
| NIC | 0 | 7 | 4 | 0 | 1 | 2 | 0 | 0 | 6 | |
| PAN | 1 | 1 | 1 | ... | ... | ... | ... | ... | 4 | |
| SLV | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ... | 0 | |
| CAR | 6 | 4 | 3 | 0 | 0 | 0 | 0 | 1 | 7 | |
| CUB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ... | 0 | |
| DOM | 12 | 22 | 22 | 0 | 0 | 0 | 0 | 0 | 55 | |
| HTI | 29 | 21 | 21 | 0 | 0 | 0 | 0 | 0 | 18 | |
| MEX | 247 | 151 | 103 | 8 | 17 | 9 | 10 | 4 | 6 | |
| CAN | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| USA | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| ARG | 6 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CHL | 9 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 9 | |
| PRY | 49 | 54 | 52 | 0 | 1 | 1 | 0 | 0 | 10 | |
| URY | 3 | 1 | 1 | ... | ... | ... | ... | ... | 11 | |
| TOTAL | 2999 | 1141 | 1036 | 32 | 30 | 27 | 10 | 6 | 5 | |

... No updated report received

Table 4
Indicators of Integrated Measles/Rubella Surveillance for Period of Weeks 01-48, 2020

| Subregion and Country | | Sites Reporting Weekly | | % Cases with Adequate Investigation | % Cases with Adequate Sample | % Blood Samples Received in Lab. ≤5 days | % Lab. Results ≤4 days | Rate of Suspected Cases Last 52 weeks (2019/49-2020/48) | | |
|---------------------------|-----|------------------------|-------------|-------------------------------------|------------------------------|--|------------------------|---|-----------------|-----|
| | | Total Units | % This Week | | | | | Measles/Rubella (100,000 pop.) | CRS (10,000 lb) | |
| AND | BOL | 3984 | ... | 88 | 93 | 72 | 88 | 0.8 | 0.0 | |
| | COL | 4612 | ... | 50 | ... | ... | ... | 1.3 | 9.6 | |
| | ECU | 2184 | ... | 99 | 71 | 33 | 61 | 1.0 | 0.0 | |
| | PER | 7781 | ... | 92 | 85 | 59 | 52 | 0.3 | 0.0 | |
| | VEN | 13092 | ... | 100 | 94 | 14 | 11 | 0.4 | 0.3 | |
| CAP | BRA | ... | ... | ... | ... | 74 | 34 | 9.5 | 0.1 | |
| | CRI | 57 | ... | 95 | 65 | 94 | 96 | 1.6 | 11.9 | |
| | GTM | 1541 | ... | 98 | 100 | 56 | 80 | 0.3 | 0.0 | |
| | HND | 469 | 90 | 97 | 100 | 83 | 100 | 1.5 | 1.7 | |
| | NIC | 185 | ... | 95 | 97 | 94 | 97 | 1.9 | 4.4 | |
| | PAN | 324 | ... | 100 | 96 | 71 | 89 | 0.7 | 0.0 | |
| | SLV | 1288 | ... | 87 | 100 | 97 | 94 | 2.7 | 0.0 | |
| | CAR | CAR | 763 | 72 | 59 | 94 | 21 | 74 | 1.0 | 1.0 |
| | LAC | CUB | 168 | ... | 100 | 100 | 100 | 100 | 12.4 | 0.0 |
| | | DOM | 247 | ... | 43 | 78 | 78 | 63 | 0.4 | 0.0 |
| | HTI | 659 | 92 | 91 | 95 | 58 | 60 | 1.1 | 2.6 | |
| MEX | MEX | 20147 | 95 | 95 | 99 | 94 | 89 | 1.9 | 0.0 | |
| NOA | CAN | ... | ... | ... | ... | ... | ... | ... | ... | |
| | USA | ... | ... | ... | ... | ... | ... | ... | ... | |
| SOC | ARG | 784 | ... | 7 | 92 | 67 | 52 | 1.0 | 0.0 | |
| | CHL | 788 | ... | 9 | 84 | 92 | 94 | 0.4 | 7.4 | |
| | PRY | 1293 | 99 | 75 | 92 | 85 | 94 | 9.2 | 0.9 | |
| | URY | 155 | ... | 67 | 33 | 38 | 38 | 0.3 | 0.0 | |
| Total and Average* | | 60521 | 36 | 85 | 96 | 76 | 47 | 4.2 | 1.1 | |

*Weighted

... No updated report received